efineptakin alfa

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
efineptakin alfa

GtoPdb Ligand ID: 11097

Compound class: Peptide

Comment: Efineptakin alfa is a long-acting immunoglobulin (Ig) fusion protein composed of recombinant human IL-7 fused to a hybrid Fc (hyFc) region of a human antibody. It comprises two disulphide bond-linked peptide chains. Efineptakin alfa has hematopoietic and immunopotentiating activities. In the oncology setting IL-7 enhances T-cell-mediated anti-tumour immune responses. Efineptakin alfa is being developed by Genexine (in-licensed to I-MAB Biopharma) and NeoImmuneTech. The peptide sequence of efineptakin alfa is claimed in Genexine's patent WO2016200219A1 as sequence 24 and would appear to be referred to as MGM-IL-7-hyFc therein [3].

References
1. EMA. IL-7 Fc Orphan designation. Accessed on 17/04/2019. Modified on 17/04/2019. EMA, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171875
2. FDA. IL-7 Fc orphan designation. Accessed on 17/04/2019. Modified on 17/04/2019. FDA, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=666218
3. Yang SH, Choi D, Lim HS. (2016) Modified interleukin-7 protein and uses thereof. Patent number: WO2016200219A1. Assignee: Genexine, Inc.. Priority date: 11/06/2015. Publication date: 15/12/2016.

References

1. EMA.
IL-7 Fc Orphan designation.
Accessed on 17/04/2019. Modified on 17/04/2019. EMA, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171875

2. FDA.
IL-7 Fc orphan designation.
Accessed on 17/04/2019. Modified on 17/04/2019. FDA, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=666218

3. Yang SH, Choi D, Lim HS. (2016)
Modified interleukin-7 protein and uses thereof.
Patent number: WO2016200219A1. Assignee: Genexine, Inc.. Priority date: 11/06/2015. Publication date: 15/12/2016.